Skip to content

CareDx CDNA Accrued expenses and other liabilities

Accrued expenses and other liabilities at other companies

NeoGenomics logo
NeoGenomicsNEO
TransMedics Group, Inc. logo
TransMedics Group, Inc.TMDX

Other financials

Income statement

See full
Revenue$117.7M+39.0%
Operating income$1.2M+109%
Net income$2.8M+127%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$78.5M-12.1%
Total debt$24.5M-19.1%
Total equity$313.5M-17.3%
Total assets$411.1M-16.0%

Cash flow

See full
Operating cash flow$4.3M+116%
CapEx$3.8M+134%
Free cash flow$514.0K+102%

Valuation

See full
Market cap$1.4B+32.2%
Enterprise value$1.35B+34.6%
P/S3.4×+0.3×

Profitability

See full
Gross margin65.5%
Operating margin-3.9%-18.3pp
Net margin-2%-19.9pp
FCF margin-0%0.0pp

Returns & leverage

See full
Return on equity-2.4%-21.9pp
Debt / equity0.1×0.0×
Current ratio3.4×-0.7×

Where this comes from

Reported directly by CareDx in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.

The official record: CareDx’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about CareDx's accrued expenses and other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CareDx's accrued expenses and other liabilities?
CareDx (CDNA) reported accrued expenses and other liabilities of $49.54M in Q1 2026.
How has CareDx's accrued expenses and other liabilities changed year-over-year?
CareDx's accrued expenses and other liabilities increased by 15.5% year-over-year, from $42.9M to $49.54M.
What is the long-term trend for CareDx's accrued expenses and other liabilities?
Over 5 years (2020 to 2025), CareDx's accrued expenses and other liabilities has grown at a 15.2% compound annual growth rate (CAGR), from $20.6M to $41.75M.